BL Pharmtech Corp.
KKRX:0651701,901.00
KRW
-24.00
(-1.25%)
ISIN
KR7065170003
Return %
Stock
S&P 500
1Y
182.89
14.39
3Y
21.34
81.42
5Y
-67.78
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Yeong-Cheol Park
- Full Time Employees
- 10
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- Yongin-si South Korea
- IPO Date
- Nov 19, 2002
- Website
- blpharmtech.com
- Similar Companies
- Business
- BL Pharmtech Corp. is a South Korea-based healthcare and biotechnology company engaged in the development, commercialization, and distribution of health functional foods, functional cosmetics, in vitro diagnostic devices, and innovative biopharmaceuticals. The company operates across multiple life sciences segments providing a diverse portfolio of products and services, including health functional foods and dietary supplements comprising red ginseng extracts, multivitamins, mineral formulations, immune enhancers, weight management products, and botanical wellness supplements; functional skincare and cosmeceutical products marketed under proprietary brands such as MOONLAB, featuring anti-aging creams, serums, and specialized dermal treatments; in vitro diagnostic devices and self-sampling screening solutions developed through its subsidiary BL Science (formerly TCM Biosciences), featuring the GynPad non-invasive cervical cancer diagnostic pad, human papillomavirus (HPV) DNA testing kits, molecular diagnostic PCR assays, and artificial intelligence-assisted clinical diagnostic tools; and biotechnology drug discovery programs driven by its subsidiary BL Melanis, focusing on Targeted Protein Degradation (TPD) and molecular glue technologies to develop novel therapeutic candidates, including the ML301 oncology pipeline targeting intractable solid tumors as well as treatments for inflammatory conditions. Founded in 1995 and headquartered in Yongin-si, Gyeonggi-do, South Korea, the company was formerly known as Next BT Co., Ltd. before rebranding to BL Pharmtech Corp. to align with the BL Group healthcare corporate identity. In recent corporate developments, BL Pharmtech executed a major strategic realignment by divesting its health functional food original equipment and design manufacturing (OEM/ODM) subsidiary, BL Healthcare Co., Ltd., to Kwangdong Pharmaceutical, allowing the company to streamline operational assets and concentrate capital on biopharmaceutical research, specialized product distribution, and next-generation diagnostic platforms. In addition, the company has expanded its oncology and drug development initiatives through research collaborations with academic and medical institutions, including the Korea Advanced Institute of Science and Technology (KAIST) and Cornell University, while continuing to advance its proprietary molecular glue degrader platform toward clinical development.